Abstract: Methods for treating Hepatitis infections are provided. In one embodiment, an initial dosage of interferon is administered to a patient, and interferon serum levels and viral load data is collected over time. This data can be used to determine patient-specific pharmacokinetic and pharmacodynamic parameters and then construct patient-specific interferon delivery profiles. Patient-specific delivery profiles can then be used to design patient-specific therapeutic regimens.

Abstract: An implantable heart monitor (IHM) implanted in a patient's body having electrogram (EGM) sense electrodes coupled with EGM sense circuitry to generate sense events upon detection of cardiac depolarizations and a blood pressure measurement transducer disposed in a heart chamber and coupled with blood pressure measurement circuitry operates to assess heart failure state as a function of mechanical pulsus alternans (MPA). MPA episodes are detected, and MPA characteristics of the MPA episode are used alone or as a group as a diagnostic marker of HF state. The MPA episode data set can be stored in memory associated with a time and date stamp. The MPA characteristics of each MPA data set in a series of MPA data sets collected over time can be compared or plotted to determine if a trend indicative of change in HF state is discernible.

Abstract: An implantable heart monitor (IHM) implanted in a patient's body having electrogram (EGM) sense electrodes coupled with EGM sense circuitry to generate sense events upon detection of cardiac depolarizations and a blood pressure measurement transducer disposed in a heart chamber and coupled with blood pressure measurement circuitry operates to assess heart failure state as a function of mechanical pulsus alternans (MPA). MPA episodes are detected, and MPA characteristics of the MPA episode are used alone or as a group as a diagnostic marker of HF state. The MPA episode data set can be stored in memory associated with a time and date stamp. The MPA characteristics of each MPA data set in a series of MPA data sets collected over time can be compared or plotted to determine if a trend indicative of change in HF state is discernible.

Abstract: A biological fluid transport device comprises a cutwater at the junction of at least two blood flow paths. The cutwater is substantially straight, substantially vertical, or both. At least one of the fluid paths may be tubular, and in some embodiments all of the fluid paths are tubular. The shear sensitive fluid may be, without limitation, blood, blood-based combinations, cell culture media, cell suspensions, proteins, and microcapsule suspensions. The device may be part of an extracorporeal circuit (e.g., blood during heart-lung bypass procedures or blood processing), but it need not be. Preferred embodiments of the device include, without limitation, kinetic pumps, mass transfer devices, filters, reservoirs, and heat exchangers.

Abstract: A biological fluid transport device comprises a cutwater at the junction of at least two blood flow paths. The cutwater is substantially straight, substantially vertical, or both. At least one of the fluid paths may be tubular, and in some embodiments all of the fluid paths are tubular. The shear sensitive fluid may be, without limitation, blood, blood-based combinations, cell culture media, cell suspensions, proteins, and microcapsule suspensions. The device may be part of an extracorporeal circuit (e.g., blood during heart-lung bypass procedures or blood processing), but it need not be. Preferred embodiments of the device include, without limitation, kinetic pumps, mass transfer devices, filters, reservoirs, and heat exchangers.